EUVIMEDDescubrir EUVIMED
Crossref

Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting

Yi-Che Huang iD, Shu-Wen Lin iD, Xavier Cheng-Hong Tsai iD, Jia-Hau Liu iD, Ming Yao iD, Fei-Yuan Hsiao iD, Yee-Chun Chen iD, Bor-Sheng Ko iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70155 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, 2026. Written by Yi-Che Huang and 7 co-authors. Institution: Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antiviral Agents. 27 references.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Whether letermovir benefits high‐risk HLA‐mismatched allogeneic hematopoietic stem cell transplantation (allo‐HSCT), particularly with GIAC‐based conditioning, is not well studied. In this retrospective real‐world analysis, we evaluated the clinical benefits of letermovir in CMV IgG‐positive recipients undergoing HLA‐mismatched allo‐HSCT (year 2011–2022) using overlap propensity score (OPS) weighting, with a prespecified subgroup included haploidentical HSCT (haplo‐HSCT) with modified GIAC (mGIAC). Among 411 transplants, 105 received letermovir, including 39 of 132 patients following the mGIAC protocol. Letermovir significantly reduced day + 180 CMV DNAemia (43.4% vs 83.2%; P < 0.001) and CMV DNAemia/disease (44.7% vs 83.4%; HR 0.33; P < 0.001), with a nonsignificant decrease in CMV disease (4.7% vs 14.2%; P = 0.101). Day + 180 and +360 survival did not differ between groups. In mGIAC haplo‐HSCT, letermovir likewise lowered day + 180 CMV DNAemia (47.5% vs 82.3%; P = 0.023) and CMV DNAemia/disease (50.9% vs 83.0%; HR 0.40; P = 0.028) without reducing CMV disease. On multivariable analyses, age ≥ 45 years and nonuse of letermovir independently increased CMV DNAemia/disease risk in both the overall and mGIAC haplo‐HSCT cohorts. Overall survival and non‐relapse mortality (NRM) were unaffected by letermovir, probably reflecting effective preemptive management and the study’s overlap‐weighted design. Based on our results, letermovir prophylaxis can effectively reduce CMV DNAemia/disease in HLA‐mismatched and mGIAC haplo‐HSCT, and may serve as a standard of care for these high‐risk patients.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsAntiviral AgentsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedPropensity ScoreCytomegalovirusDNA, ViralHLA AntigensYoung AdultTreatment OutcomeAcetatesQuinazolines

Substances

letermovirAntiviral AgentsDNA, ViralHLA AntigensAcetatesQuinazolines

Authors and institutions

  • Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Pharmacy, Taipei Medical University, Shuang Ho Hospital, New Taipei City, Taiwan.
  • School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

ORCID profiles: Yi-Che Huang, Shu-Wen Lin, Xavier Cheng-Hong Tsai, Jia-Hau Liu, Ming Yao, Fei-Yuan Hsiao, Yee-Chun Chen, Bor-Sheng Ko

Cite

APA

Huang, Y. C., Lin, S. W., Tsai, X. C., Liu, J. H., Yao, M., Hsiao, F. Y., Chen, Y. C., & Ko, B. S. (2026). Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70155

Vancouver

Huang YC, Lin SW, Tsai XC, Liu JH, Yao M, Hsiao FY, et al. Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70155

BibTeX
@article{Huang2026,
  author = {Huang, Yi-Che and Lin, Shu-Wen and Tsai, Xavier Cheng-Hong and Liu, Jia-Hau and Yao, Ming and Hsiao, Fei-Yuan and Chen, Yee-Chun and Ko, Bor-Sheng},
  title = {Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70155}
}
Start for free →